An article in the New England Journal of Medicine asks whether settlements such as the $3 billion GlaxoSmithKline agreed to last July regarding off-label marketing of Paxil and Wellbutrin are sufficient to change corporate behavior, and proposes possible improvements to the system.
Outterson, J. “Punishing Health Care Fraud – Is the GSK Settlement Sufficient?
